The Federal Commission for Protection against Sanitary Risks (Cofeprisapproved four clinical trials of medications that might help treat the infection coronavirus Covid-19 reported Hugo Lopez-Gatell Ramirez, deputy secretary of Prevention and Health Promotion.
In National Palace, the official mentioned that at the moment there are four clinical trials-to-door, some will start the following week.
“When the epidemic began, it was agreed that Mexico is to join fields that apply to clinical trials or experiences public health. Cofepris approved three trials and is in the process of liberation of the authorization of the fourth, are collaborations with researchers from national institutes of health of the united States,” he said.
A clinical trial is about the use of the drug “remdesivir”, which is an antiviral that has been used little in the world, but it looks “promising” for the preliminary investigations in order to combat the coronavirus, explained the official.
The second is an essay about the medicine, “tocilizumab”, it is a protein that blocks one of the mechanisms that causes inflammation of tissues in particular of the lung tissue, “and that, because inflammation on the lungs is the main cause of acute lung injury severe, it is considered promising for the use of this drug,” he said.
The third clinical trial is on hydroxychloroquine, a medicine used for years in the treatment against malaria, it also is used for immune modulation in rheumatic diseases. The last essay is the combination of chloroquine with the antibiotic azithromycin.
“It is noteworthy that, even though we see news international push because the immediate use of these products, we have to be clear that this does not work the safety in the use of innovative new medicines, or existing to treat new diseases, it must verify that its use does not cause damage on people, there are international standards that Mexico is to ensure adequate biosecurity, the protection of human beings, the quality of the research and ethics”.